Article Text

other Versions

PDF

Original research article
A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
  1. Iryna Schlackow1,
  2. Seamus Kent1,
  3. William Herrington2,
  4. Jonathan Emberson2,
  5. Richard Haynes2,
  6. Christina Reith2,
  7. Christoph Wanner3,
  8. Bengt Fellström4,
  9. Alastair Gray1,
  10. Martin J Landray2,
  11. Colin Baigent2,5,
  12. Borislava Mihaylova1
  13. On behalf of the SHARP Collaborative Group
  1. 1 Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK
  2. 2 Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
  3. 3 Division of Nephrology, Department of Medicine, University Hospital of Würzburg, Würzburg, Germany
  4. 4 University Hospital, Uppsala, Sweden
  5. 5 Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
  1. Correspondence to Dr Borislava Mihaylova, Health Economic Research Centre, Nuffield Department of Population Health, Old Road Campus, Oxford OX3 7LF, UK; boby.mihaylova{at}dph.ox.ac.uk

Abstract

Objective To present a long-term policy model of cardiovascular disease (CVD) in moderate-to-advanced chronic kidney disease (CKD).

Methods A Markov model with transitions between CKD stages (3B, 4, 5, on dialysis, with kidney transplant) and cardiovascular events (major atherosclerotic events, haemorrhagic stroke, vascular death) was developed with individualised CKD and CVD risks estimated using the 5 years’ follow-up data of the 9270 patients with moderate-to-severe CKD in the Study of Heart and Renal Protection (SHARP) and multivariate parametric survival analysis. The model was assessed in three further CKD cohorts and compared with currently used risk scores.

Results Higher age, previous cardiovascular events and advanced CKD were the main contributors to increased individual disease risks. CKD and CVD risks predicted by the state-transition model corresponded well to risks observed in SHARP and external cohorts. The model's predictions of vascular risk and progression to end-stage renal disease were better than, or comparable to, those produced by other risk scores. As an illustration, at age 60–69 years, projected survival for SHARP participants in CKD stage 3B was 13.5 years (10.6 quality-adjusted life years (QALYs)) in men and 14.8 years (10.7 QALYs) in women. Corresponding projections for participants on dialysis were 7.5 (5.6 QALYs) and 7.8 years (5.4 QALYs). A non-fatal major atherosclerotic event reduced life expectancy by about 2 years in stage 3B and by 1 year in dialysis.

Conclusions The SHARP CKD-CVD model is a novel resource for evaluating health outcomes and cost-effectiveness of interventions in CKD.

Trial registration number NCT00125593 and ISRCTN54137607; Post-results.

  • chronic kidney disease
  • cardiovascular risk
  • CKD progression
  • markov model
  • life expectancy

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

Statistics from Altmetric.com

Background

Chronic kidney disease (CKD) contributes significantly to the global burden of disease. The prevalence of CKD stages 3 and above in the adult UK population in 2009/2010 was 6% and is expected to rise with ageing populations and increasing prevalence of diabetes. Cardiovascular and all-cause mortality are increased in CKD,1 2 with most patients with CKD dying before reaching end-stage renal disease.3 Conversely, cardiovascular disease (CVD) is associated with increased risk of CKD progression.4 Policy models, used to evaluate long-term effectiveness and cost-effectiveness of interventions in CKD, need to account for this interdependence.

In published long-term CKD models,5–7 the cardiovascular risks have been based on Framingham risk equations, adjusted for an increased hazard with CKD5 6 or data from population with only mildly impaired renal function7; and the risk of CKD progression is either assumed independent from5 7, or is only partially adjusted for6, known risk factors. In two published models, dialysis and transplantation are not considered separately5 6 despite large differences in outcomes,8 and assessment of model performance is limited to comparisons with published data.6 7

We present a policy model in moderate-to-advanced CKD developed using the detailed individual participant data of the Study of Heart and Renal Protection (SHARP), which overcomes many of these limitations. The model allows for the interdependence between CKD and cardiovascular complications and simulates the progression of CKD, experience of cardiovascular events and death, health-related quality of life and healthcare costs. The model was validated internally, in several external datasets and against existing risk scores.

Methods

The Study of Heart and Renal Protection

Details of SHARP were reported previously.9 10 Briefly, patients with CKD aged ≥40 years with ≥2 previous measurements of serum or plasma creatinine ≥1.7 mg/dL (150 µmol/L) in men or ≥1.5 mg/dL (130 µmol/L) in women, but without life-limiting conditions, history of myocardial infarction or coronary revascularisation or functioning or planned kidney transplant, were eligible. At study entry, information was collected on sociodemographic characteristics (age, gender, ethnicity, number of children and adult dependants, highest level of education), physical measurements (body mass index (BMI), systolic and diastolic blood pressure), lipids (including total and high density lipoprotein  (HDL) cholesterol)), other laboratory measurements (albumin, haemoglobin and phosphate), smoking status, urinary albumin:creatinine ratio (uACR), cause of kidney disease and history of CVD and diabetes. At study visits, scheduled at 2, 6, 12 months and every 6 months thereafter, information was recorded about myocardial infarctions, strokes, vascular procedures, hospital admissions and other serious adverse events.

SHARP CKD-CVD lifetime outcomes model

The SHARP CKD-CVD decision analytic model includes a CKD submodel, simulating progression of CKD, and CVD submodel, simulating experience of fatal and non-fatal cardiovascular events and non-vascular death. The submodels are summarised below; further detail is provided in online supplementary item S1. For each participant, the annual risks of CVD and CKD endpoints were estimated using multivariate risk equations with a range of baseline characteristics and time-updated age, time since CKD diagnosis, CVD history (including within-trial events) and CKD status at end of previous year.

Supplementary Material

Supplementary material 1

CVD submodel

The annual risks of three nested composite cardiovascular endpoints were evaluated: (1) vascular death (ie, coronary, stroke or other vascular death), (2) vascular death or non-fatal major atherosclerotic event (ie, vascular death, myocardial infarction, non-haemorrhagic stroke or arterial revascularisation), and (3) vascular death or non-fatal major vascular event (ie, vascular death, myocardial infarction, any stroke or arterial revascularisation). Parametric proportional hazard multivariate survival models (Exponential, Weibull or Gompertz selected using the Akaike information criterion (AIC11) were estimated to support extrapolation over a patient's lifetime.

CKD submodel

For each year of follow-up, data collected during that year were used to categorise participants into one of five CKD states: CKD stage 3B (estimated glomerular filtration rate (eGFR): 30≤ eGFR <45 mL/min/1.73 m2), CKD stage 4 (15≤ eGFR <30 mL/min/1.73 m2), CKD stage 5 (eGFR <15 mL/min/1.73 m2) but not yet receiving renal replacement therapy (RRT: maintenance dialysis or kidney transplant), on maintenance dialysis, and with a kidney transplant.

In each year, participants not on RRT could progress to (or remain in) any CKD category, with transition probabilities estimated using multivariate multinomial logistic regression. For participants on dialysis, the probability of receiving a kidney transplant was estimated using logistic regression. Due to the small number of kidney transplants that failed between years of follow-up in SHARP, a constant annual probability of a transplant failing was estimated based on the overall failure rate observed in the study.

SHARP CKD-CVD model structure

The CVD and CKD submodels were combined into the SHARP CKD-CVD model, a Markov model with an annual cycle of transition (figure 1). A cohort simulation12 was used to evaluate health outcomes and costs for individual participants annually until death or 95 years of age. The model states were defined by the most recent event (non-vascular death, vascular death, non-fatal major atherosclerotic event or non-fatal haemorrhagic stroke; CVD submodel) and the most recent CKD status (CKD stage 3B, CKD stage 4, CKD stage 5 not on RRT, on dialysis, with kidney transplant; CKD submodel). Together, the model states comprise all possible combinations of non-fatal CVD (including no previous CVD) and CKD states, as well as two fatal states: vascular and non-vascular death. Parameter uncertainty was assessed using the bootstrap method12 with 1000 resamples of risk equations, and confidence intervals were derived using the equal-tailed percentile method.

Figure 1

Schematic of the SHARP CKD-CVD lifetime health outcomes model. 1A small number of participants had estimated glomerular filtration rate ≥45 mL/min/1.73 m2 at entry into the study; 2Cox proportional hazards model derived from SHARP data used in internal validation. UK population data used to derive annual non-vascular mortality rates in the model. CKD, chronic kidney disease; CVD, cardiovascular disease; MAE, major atherosclerotic event; RRT, renal replacement therapy; SHARP, Study of Heart and Renal Protection.

Model validation

Model-simulated cumulative rates of cardiovascular endpoints (all participants) and progression to RRT (those not on RRT at entry) were internally validated through comparison with the 5-year Kaplan-Meier product-limit estimates in SHARP, across all participants, and in subgroups by CKD status. Model discrimination was assessed using Harrell's c-index for a censored response.13 In further validation, data from the Chronic Renal Impairment in Birmingham (CRIB), prospective observational study of 382 patients with CKD stage 3–514 and two randomised trials in dialysis patients, the Der Deutsche Diabetes Dialyse Studie (4D) (1255 patients with type 2 diabetes mellitus receiving maintenance haemodialysis15) and A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events (AURORA) (2776 patients on maintenance haemodialysis16), were used. Kaplan-Meier curves and Harrell's c-index were used to assess calibration and discrimination, respectively.

The SHARP CKD-CVD model was also assessed against recommended risk scores. First, the 5-year risks of a major vascular event or vascular death in participants without previous CVD or diabetes in SHARP and AURORA were calculated using (1) the Pooled Cohort Risk Equations17 18 and (2) the SHARP CKD-CVD model, and compared with observed rates. Second, the 5-year risk of progressing to RRT (ie, initiation of dialysis or renal transplantation) among SHARP participants not on dialysis at study entry, and among CRIB participants, was calculated using (1) the model by Tangri et al for progression of CKD to kidney failure19 and (2) the SHARP CKD-CVD model, and compared with the observed rates.

Health-related quality of life

Of the 7018 SHARP participants alive at the final follow-up, 6356 completed the EuroQol 5-dimensions 3-level (EQ-5D-3L) questionnaire (including mobility, self-care, usual activities, pain/discomfort and anxiety/depression quality-of-life dimensions).20 The responses were used to calculate utilities using the UK EQ-5D-3L tariff,21 taking values between 1 (full health) and −0.596 (worse than death; 0 corresponds to death). Linear regression was used to model the effects of participant characteristics on quality of life and predict patient's quality of life during each annual period in the model.

Hospital care costs

Annual hospital care costs associated with model states, derived from SHARP,22 were implemented in the model.

Results

In SHARP, 9270 participants with moderate-to-advanced CKD were followed for an average of 4.9 years (total 39 386 person-years).9 At study entry, mean age was 62 years (SD 12), 5800 participants (63%) were male, 5152 (56%) were recruited in Europe, 6646 (72%) were white, 2094 (23%) had diabetes and 1393 (15%) had prior vascular disease (see online supplementary table S1).

In total, 736 vascular deaths, 1753 major atherosclerotic events or vascular deaths and 1785 major vascular events or vascular deaths contributed to cardiovascular risks’ estimation (see online supplementary table S2). Of the 6235 participants not on RRT at entry, 1739 (28%; of which 913 were in CKD stage 5 not on RRT) initiated dialysis and 462 (7%; of which 255 were in CKD stage 5 not on RRT) received kidney transplants during the study. Of the 3025 participants on dialysis at entry, 669 received kidney transplants. Excluding transplants failing in the year of transplantation, the annual probability of transplant failure in SHARP in the model was 1.3% (see online supplementary table S3).

Cardiovascular risk equations

Non-fatal cardiovascular events were strongly associated with an increased subsequent cardiovascular risk, with the increase greatest in the first year (table 1). Compared with participants without vascular disease, vascular death rates were three times higher (hazard ratios (HR)) 3.0 (95%CI 2.2 to 4.0)) in the year following a major atherosclerotic event, more than twice as high (HR 2.6 (1.7–3.9)) in the subsequent year and remained 50% higher (HR 1.5 (0.9–2.7)) thereafter. Following a non-fatal major atherosclerotic event, the HRs for another such event or death from a vascular cause in the first, second and subsequent years were 4.3 (3.6–5.2), 3.5 (2.7–4.6) and 2.3 (1.6–3.3), respectively.

Table 1

Multivariate risk equations in the SHARP CKD-CVD lifetime outcomes model

More advanced CKD status was also associated with increased cardiovascular risk (table 1). After adjustment for covariates, compared with participants in CKD stage 3B, the risk of dying from vascular causes in the exponential proportional hazards survival model was about twice as high in participants in stage 4 or stage 5 not on RRT (HR 1.7 (1.3–2.3) and HR 2.2 (1.6–3.1), respectively) and three to four times higher in those on dialysis (HR 2.8 (2.0–4.0) for participants with RRT duration <3 years and HR 4.1 (2.7–6.1) for those with RRT duration ≥3 years). A graded association was also observed for major atherosclerotic event or vascular death risk in the Gompertz proportional hazards model (compared with CKD stage 3B, HR 1.3 (1.1–1.5) for participants in stage 4, HR 1.6 (1.3–2.0) for participants in stage 5, HR 2.1 (1.7–2.7) for participants on dialysis with RRT <3 years and HR 2.5 (1.9–3.3) for participants on dialysis with RRT ≥3 years). Participants in receipt of RRT at entry were at further increased cardiovascular risk conferred through the hazard for the separate RRT category in the uACR covariate (table 1). Cardiovascular risks in participants with kidney transplants were similar to those in CKD stage 3B (HR 0.9 (0.4–2.0) for risk of vascular death and HR 0.7 (0.5–1.2) for risk of major atherosclerotic event or vascular death).

CKD risk equations

The main predictor of CKD progression was previous CKD stage (table 1). Compared with participants in CKD stage 3B, participants in stage 4 were almost 11 times more likely to progress to stage 5 (relative risk ratio 10.8 (95%CI 6.8 to 17.0)) and 2.6 times (1.6–4.0) more likely to start dialysis the following year than to remain in stage 4. Similarly, among participants in CKD stage 4, compared with participants with baseline uACR <30 mg/g, those with baseline uACR of 30–300 mg/g were 1.7 times (1.5–2.0) more likely to progress to stage 5 and 1.7 times (1.3–2.1) more likely to start dialysis the following year than to remain in stage 4.

Effects of CVD events and CKD progression on health-related quality of life

Cardiovascular events and on dialysis status were the main determinants of quality of life (table 2). Major vascular events were associated with reductions in EQ-5D utility of 0.17 (95%CI 0.14 to 0.21) in the year of event and 0.10 (0.08–0.13) in subsequent years, while on dialysis status was associated with a reduction of 0.06 (0.04–0.07).

Table 2

Health-related quality of life in moderate-to-advanced chronic kidney disease: a linear regression model derived from Study of Heart and Renal Protection data

Model validation

The cumulative event rates predicted by the SHARP CKD-CVD model closely matched observed rates for almost all years of follow-up and all participant subgroups (figure 2), and Harrell's c-index showed good discrimination for all disease endpoints (see online supplementary table S4).

Figure 2

Predicted and observed Kaplan-Meier cumulative risks in SHARP (internal validity). For the progression to renal replacement therapy (RRT) endpoint, only participants in pre-RRT stages at baseline were included. Lipid-lowering treatment use was simulated as the percentage of participants using any lipid-lowering medication in the respective treatment arm and year of follow-up in SHARP. CKD, chronic kidney disease; CVD, cardiovascular disease; SHARP, Study of Heart and Renal Protection.

Participants in CRIB, 4D and AURORA differed from participants in SHARP (see online supplementary table S5), being more likely to have had vascular disease at entry. Also, while participants on dialysis at entry into SHARP had been on dialysis for an average of 2.5 (SD 3.1) years, those in 4D had received dialysis for an average of 0.7 (0.6) years and those in AURORA for 4.4 (5.2) years. In the predialysis CRIB cohort, SHARP CKD-CVD model predictions showed good agreement with observed risks of vascular death and progression to RRT in most subgroups and years (figure 3). In the 4D dialysis cohort, the agreement between predicted and observed risks was good for vascular death but a 14% higher rate was predicted for the combined endpoint by year 5 (figure 3). In the AURORA dialysis cohort, the model captured the trends in events over time but the predicted rates of major vascular events or vascular deaths and of vascular death alone were 19% and 35% lower, respectively, by year 5 (figure 3). In these external cohorts, Harrell's c-index indicates that the model discriminates risk well in predialysis (c-index in CRIB 0.75 to 0.84) but its ability to discriminate risk in dialysis might be more limited (c-index 0.65 in AURORA; 0.58 to 0.61 in 4D; see online supplementary table S4).

Figure 3

Predicted and observed Kaplan-Meier cumulative risks in CRIB, 4D and AURORA (external validity). The predictions were simulated in the absence of study lipid-lowering treatments in 4D and AURORA; information on non-coronary revascularisation was not available in 4D. Transplantation rates calibrated to correspond to rates in 4D and AURORA; no other calibration was performed. AURORA, A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events; CKD, chronic kidney disease; CRIB, Chronic Renal Impairment in Birmingham; CVD, cardiovascular disease; RRT, renal replacement therapy; 4D, Der Deutsche Diabetes Dialyse.

The cardiovascular risk predictions by the Pooled Cohort Equations could not capture variation in risk across CKD stages, unlike predictions from the SHARP CKD-CVD model, with deviations particularly pronounced among SHARP participants in CKD stage 3B and those on dialysis (table 3). The 5-year rates of progression to RRT predicted by the SHARP CKD-CVD and the Tangri models were both close to the observed rates among pre-RRT SHARP and CRIB participants.

Table 3

Comparison of predictions of 5-year risk of a major vascular event or vascular death and initiation of RRT by the SHARP CKD-CVD model and external risk models

We illustrate the use of the model in two applications.

Application 1: prediction of long-term outcomes in CKD

The CKD-CVD model was used to project survival for SHARP participants using their baseline characteristics. The model predicted marked variation in survival by CKD stage (figure 4, online supplementary table S6). Among participants aged 60–69 years in CKD stage 3B, men were predicted to survive a further 13.5 (95%CI 13.2 to 13.9) years (10.6 (10.3–10.9) quality-adjusted life years (QALYs)) and women 14.8 (14.4–15.3) years (10.7 (10.3–11.1) QALYs). However, corresponding predictions for those on dialysis were only 7.5 (7.2–7.8) years (5.6 (5.4–5.9) QALYs) and 7.8 (7.5–8.1) years (5.4 (5.2–5.6) QALYs). At ages 60–69, a major, but non-fatal, atherosclerotic event was predicted to reduce life expectancy by 1.7 (0.8–2.5) years (2.3 (1.6–3.0) QALYs) for a man in CKD stage 3B and 2.0 (1.0–2.9) years (2.6 (1.8–3.2) QALYs) for a woman in CKD stage 3B. Corresponding results for those on dialysis were 0.9 (0.3–1.4) years (1.2 (0.8–1.6) QALYs) and 0.8 (0.3–1.4) years (1.1 (0.7–1.5) QALYs).

Figure 4

Predicted life expectancy (years) and quality-adjusted life-years for participants in SHARP. The predictions are for SHARP participants in the absence of lipid-lowering treatment. *Major atherosclerotic event is assumed to occur in year prior to entry in the model. CKD, chronic kidney disease; QALYs, quality-adjusted life years; RRT, renal replacement therapy; SHARP, Study of Heart and Renal Protection.

Application 2: prediction of risk in individual patients with CKD

The SHARP CKD-CVD model can predict disease risks in people with CKD given their individual demographic and clinical characteristics. For example, the 5-year major vascular event risk for a patient with stage 4 CKD is 7% (95%CI 5% to 9%) for a 50-year-old male with cystic kidney disease but no other cardiovascular risk factors or comorbidities, and 49% (40%–59%) for a 70-year-old male with diabetic nephropathy and prior CVD (table 4). Similarly, the predicted 5-year death risk is 33% (31%–34%) for a 60-year female without major comorbidity at dialysis initiation, but is only 13% (13%–14%) if she is transplanted.

Table 4

An illustrative model application: 5-year risk of adverse outcomes in selected patients

Model web interface

The SHARP CKD-CVD model interface and user guide are available at http://dismod.ndph.ox.ac.uk/kidneymodel/app/.

Discussion

The SHARP CKD-CVD model, developed using the detailed data from the 9270 participants with moderate-to-advanced CKD in SHARP, projects long-term cardiovascular event risk, kidney disease progression and (quality-of-life adjusted) survival. The estimated graded associations between more advanced CKD and higher cardiovascular risk and subsequent adverse renal and cardiovascular outcomes are consistent with published data.2 23 24 The model's discrimination of risk was very good in participant categories in SHARP and predialysis CRIB cohorts, good in the dialysis AURORA cohort and informative, though more limited, in the dialysis 4D cohort with differences potentially due to the more homogeneous populations in AURORA and 4D (eg, 4D participants were with diabetes and both 4D and AURORA participants had substantially more cardiovascular comorbidities at entry). The ability of the model to discriminate risk reasonably well across moderate-to-advanced CKD categories suggests that the risk equations capture the important risk factors. The model's ability to predict risks in external cohorts showed good performance in CRIB and 4D, but less consistent performance in AURORA, perhaps due to differences in cardiovascular comorbidity and the substantially longer duration spent on dialysis by AURORA patients at entry into the study. The model showed better ability to predict cardiovascular risk in SHARP participants than that of the Pooled Cohort Equations,17 18 and its ability to predict progression to RRT was comparable to that of the Tangri et al model.19

By contrast with the previously published models,5–7 the SHARP CKD-CVD model was derived entirely using the individual participant data from a large CKD cohort with adjudicated endpoints. The model takes account of the interdependence between kidney and cardiovascular diseases, includes separate kidney transplant and dialysis states and accounts for the effects of uncertainty in all model parameters on predictions. The freely available model interface allows adaptations to other settings, as well as simulation of patient outcomes with different cardiovascular interventions.

Potential limitations should be acknowledged. First, SHARP participants were followed for an average of 5 years and hence the longer term predictions are guided by the model structure and parametric proportional hazards assumptions. Nevertheless, the annual updating of age, CVD history and CKD status captures well the changes in hazard over time; the proportional hazards assumptions were satisfied in the survival models and supported in external validations; and the parameter uncertainty was fully incorporated. Second, SHARP excluded patients with major coronary disease, whereas in routine clinical practice coronary heart disease is highly prevalent in moderate-to-advanced CKD.25 While the inclusion of incident coronary events as time-updated covariates in risk equations enables the prediction of risks for kidney patients with coronary disease, model assessment in further CKD cohorts is desirable. Finally, future model developments could consider further disease markers and endpoints (eg, heart failure and sudden cardiac death,26 fractures, infections or cancers27 28).

The SHARP CKD-CVD model contributes to a greater understanding of risks of cardiovascular complications in CKD and will be useful to clinicians, analysts and policymakers to simulate long-term outcomes for their patients with CKD and evaluate the comparative effectiveness and cost-effectiveness of interventions to reduce cardiovascular risk.

Key messages

What is already known on this subject?

Chronic kidney disease (CKD) increases the risk of cardiovascular disease (CVD) and, conversely, CVD may affect kidney disease progression. Policy models to project the long-term health outcomes in people with CKD accounting for this interdependence, as well as for individual patients’ risk profiles, are unavailable.

What does the study add?

The Study of Heart and Renal Protection (SHARP) CKD-CVD model, developed using detailed data from nearly 10 000 patients with moderate-to-advanced CKD followed for an average of 5 years, projects lifetime cardiovascular event risks, kidney disease progression and (quality-of-life adjusted) survival. The model performs well in categories of patients by CKD stage in SHARP and in external CKD cohorts. A flexible user-friendly web interface, which also includes projection of healthcare costs, is freely available to facilitate model use.

How might this impact on clinical practice?

The model can be used by clinicians to evaluate long-term risks for their patients and discuss possible treatment options, as well as by analysts and policy makers to evaluate the comparative effectiveness and cost-effectiveness of interventions to manage cardiovascular complications in CKD.

Acknowledgments

The authors thank the Study of Heart and Renal Protection (SHARP) participants and the local clinical centre staff, regional and national coordinators, steering committee and data monitoring committee. A full list of the SHARP investigators is available elsewhere.9 The authors also thank the UK Renal Registry (Retha Steenkamp and Damian Fogarty) for providing more detailed mortality data.

References

View Abstract

Footnotes

  • Contributors Research idea and study design: BM, IS, WH, JE, RH, AG, MJL, CB; data acquisition: CB, MJL, WH, RH, CR, CW, BF; data analysis and interpretation: IS, BM, SK, WH, JE, RH, CR, MJL, CB; supervision or mentorship: BM, CB. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. BM and IS take responsibility that this study has been reported honestly, accurately and transparently; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

  • Funding The study was funded by Merck & Co., Whitehouse Station, NJ USA, with additional support from the Australian National Health Medical Research Council, the British Heart Foundation (CH/1996001/9454) and the UK Medical Research Council (A310). SHARP was initiated, conducted and interpreted independently of the principal study funder (Merck & Co.).

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval Ethical approval was obtained from all study sites prior to enrollment into SHARP.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement The procedure for considering requests for access to the SHARP data is available at the CTSU website (www.ctsu.ox.ac.uk\).

  • Collaborators The SHARP Collaborative Group steering committee comprises R. Collins (chair), C. Baigent (study coordinator and chief investigator), M.J. Landray (clinical coordinator and co-principal investigator), C. Bray, Y. Chen (administrative coordinators), A. Baxter, A. Young (computing coordinators), M. Hill (director, central laboratory), C. Knott (nursing coordinator), A. Cass, B. Feldt-Rasmussen, B. Fellström, D.E. Grobbee, C. Grönhagen-Riska, M. Haas, H. Holdaas, L.S. Hooi, L. Jiang, B. Kasiske, U. Krairittichai, A. Levin, Z.A. Massy, V. Tesar, R. Walker, C. Wanner, D.C. Wheeler, A. Wiecek (national coordinators), T. Dasgupta, W. Herrington, D. Lewis, M. Mafham, W. Majoni, C. Reith (clinical support), J. Emberson, S. Parish (statistics), D. Simpson (lay member), J. Strony, T. Musliner (Merck Schering Plough, non-voting), L. Agodoa, J. Armitage, Z. Chen, J. Craig, D. de Zeeuw, J. M. Gaziano, R. Grimm, V. Krane, B. Neal, V. Ophascharoensuk, T. Pedersen, P. Sleight, J. Tobert and C. Tomson.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.